Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Schedule of Revenue Associated with License Agreement

We recognized revenue associated with the KKC Commercialization Agreement for the periods presented (in thousands):

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2023		2022		2023		2022
Timing of Revenue Recognition:
Services performed over time	$	—	$	32,473	$	743	$	40,832
Pass through services at a point in time		—		262		9		633
	$	—	$	32,735	$	752	$	41,465

Schedule of Changes in Unbilled Receivables and Contract Liabilities

Contract balances are as follows (in thousands):

	December 31, 2023		June 30, 2023		June 30, 2022
Unbilled receivables	$	—	$	85	$	10,044
Contract liabilities included in deferred revenue and deferred     revenue, net of current portion	$	—	$	317	$	30,900

A reconciliation of the beginning and ending amount of contract liabilities, which are primarily related to the combined performance obligation for the transfer of development services under the KKC Commercialization Agreement, which are a separate performance obligation in the Company’s contracts pursuant to research plans under the agreements, was as follows for the periods presented, (in thousands):

	December 31, 2023			June 30, 2023
Beginning balance	$	317		$	30,900
Recognized as revenue:
Revenue recognized upon satisfaction of performance obligations		(317	)		(5,411	)
Revenue recognized from change in estimate for performance obligations     that are being closed		—			(16,565	)
Revenue recognized for performance obligations that will no longer     commence		—			(8,607	)
Ending balance	$	—		$	317

Antidilutive Securities

The following table presents potentially dilutive shares excluded from the calculation of diluted net income (loss) per share (in thousands):

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2023		2022		2023		2022
Stock options		1,398		1,372		1,398		1,380
Warrants		103		802		103		802
Restricted stock units		—		—		—		—
Total anti-dilutive shares		1,501		2,174		1,501		2,182